Corporate Greed Case Study: Pure Instinct & Its Impact on Consumers Alleging Deceptive Practices
TLDR: Consumers have filed a class-action lawsuit against Pure Instinct, makers of popular pheromone-infused fragrances, alleging the company’s core marketing claims are a scientific sham. The lawsuit contends that Pure Instinct knowingly deceives customers by advertising its products as containing “human-compatible pheromones” capable of attracting others, despite scientific evidence suggesting humans cannot detect such pheromones and that the chemicals used are not proven to have the advertised effects. This alleged deception, aimed at boosting profits, has led to consumers wasting money on products that, according to the legal complaint, don’t deliver on their fundamental promise.
Read on for a deep dive into the allegations and the systemic issues they represent.
Table of Contents
- Introduction: The Allure of Attraction, The Sting of Alleged Deception
- Inside the Allegations: Deconstructing Pure Instinct’s Pheromone Promise
- A Timeline of Alleged Deception
- Regulatory Gaps: How “Scientifically Proven” Claims Can Evade Scrutiny
- Profit-Maximization Over Truth: The Lure of a Multi-Million Dollar Misrepresentation
- The Economic Fallout: Consumers Left Empty-Handed
- Public Health Under a False Pretense: Misbranded Aphrodisiacs and Consumer Trust
- The PR Machine: Weaving a Narrative of Scientific Legitimacy
- Corporate Greed in a Bottle: Exploiting Desires for Profit
- The Pervasive Nature of Misleading Marketing in Neoliberal Economies
- Corporate Accountability in Late-Stage Capitalism: A System Under Strain
- Pathways for Reform: Strengthening Consumer Protection in an Era of Pseudoscience
- This Is the System Working as Intended: Profit Over People
- Conclusion: Beyond Fragrance, A Question of Corporate Integrity
- Frivolous or Serious Lawsuit? Assessing the Claims Against Pure Instinct
1. Introduction: The Allure of Attraction, The Sting of Alleged Deception
In a world saturated with products promising enhanced appeal, Pure Instinct’s pheromone-infused fragrances stood out, claiming a scientific basis for their allure. Consumers, drawn by the promise of “human-compatible pheromones” capable of influencing moods, emotions, and attraction, purchased these perfumes, colognes, and body sprays.
However, a class-action lawsuit filed in the United States District Court for the Central District of California paints a vastly different picture, alleging that these claims are not just exaggerated, but “scientifically false.”
The lawsuit, spearheaded by plaintiff India Winslow, accuses defendants W.T.F.N. Inc. and Oui Lab, Inc. (collectively “Pure Instinct”) of building a lucrative business on a foundation of deception.
At the heart of the complaint is the assertion that humans lack the biological hardware—specifically a functioning vomeronasal organ (VNO)—to detect pheromones in the way the company’s marketing materials suggest.
This legal challenge brings to light not only the specific allegations against Pure Instinct but also broader, systemic issues of corporate misconduct, where the pursuit of profit can allegedly lead to widespread consumer deception, often flourishing in the gaps left by deregulation and lax oversight characteristic of neoliberal capitalism.
2. Inside the Allegations: Deconstructing Pure Instinct’s Pheromone Promise
The legal complaint meticulously details how Pure Instinct allegedly misled consumers.
The company’s products are prominently labeled with terms like “Pheromone” and “pheromone infused.” Their marketing, including their website and product descriptions, boldly states that the products contain “human-compatible pheromones capable of influencing moods, emotions, and affection and triggering social responses,” even claiming, “It’s not myth, it’s science.”
However, the lawsuit contends this is a fabrication. It argues that humans do not emit and cannot detect pheromones because they lack a functioning vomeronasal organ (VNO), the very organ Pure Instinct’s website allegedly claimed was responsible for detecting these chemicals.
The legal complaint cites research indicating the human VNO is “repeatedly reviewed as nonfunctional” and that genes coding for vomeronasal receptor proteins are “mutated and are non-functional” in humans. One study referenced concluded that “these results provide strong evidence that the human VNO has no obvious function.”
Furthermore, the lawsuit challenges the specific chemicals Pure Instinct represents as “human-compatible pheromones”—androstadienone and copulin. Citing scientific reviews and studies, the complaint asserts that androstadienone has “never been shown to be a human pheromone” and that exposure to it had “no significant effect” on attractiveness ratings in a double-blind study.
Similarly, a study on synthetic copulin reportedly found “no effects on men’s sexual behavior,” leading researchers to state that “copulin should stop being termed a putative human pheromone or even a chemical signal.”
Plaintiff India Winslow stated she purchased a Pure Instinct product in March 2022, relying on the representation that it contained pheromones capable of attracting others.
Had she known this was allegedly false, she claims she would not have purchased the product or would have paid significantly less. This sentiment is extended to a proposed nationwide class of consumers who, the lawsuit argues, were financially injured by these deceptive marketing practices.
A Timeline of Alleged Deception
| Date | Event |
| March 2022 | Plaintiff India Winslow purchased Pure Instinct True Blue Pheromone Body Spray based on alleged misrepresentations. |
| October 22, 2024 | A CLRA (Consumers Legal Remedies Act) demand letter was sent to Defendant WTFN Inc. providing notice of alleged violations. |
| October 25, 2024 | Defendant Oui Lab, Inc. was deemed to have received constructive notice of the CLRA allegations via the notice to WTFN Inc. |
| February 14, 2025 | A CLRA demand letter was sent directly to Defendant Oui Lab, Inc. regarding its alleged violations. |
| February 19, 25 | Class Action Complaint (Case 2:25-cv-01393) was filed in the United States District Court, Central District of California. |
3. Regulatory Gaps: How “Scientifically Proven” Claims Can Evade Scrutiny
The alleged misconduct by Pure Instinct highlights significant gaps in regulatory oversight, particularly concerning products that blur the lines between cosmetics and drugs.
The legal complaint points to the Food and Drug Administration (FDA) regulation 21 C.F.R. § 310.528(a), which classifies any product claiming to “arouse or increase sexual desire” as an aphrodisiac drug product. Such products are deemed misbranded unless they receive FDA approval.
Crucially, the FDA has stated there is “a lack of adequate data to establish general recognition of the safety and effectiveness of any of these ingredients, or any other ingredient, for OTC use as an aphrodisiac.” This essentially means that labeling claims for over-the-counter aphrodisiacs are considered “false, misleading, or unsupported by scientific data” by the FDA.
The lawsuit argues that Pure Instinct’s products, by promising to influence attraction, fall into this category and, lacking FDA approval, are misbranded under federal and, by extension, California law (the Sherman Food Drug and Cosmetic Law).
This situation reflects a common tactic in neoliberal economies where deregulation and under-enforcement can create fertile ground for companies to make bold, scientifically questionable claims with minimal pre-market scrutiny, leaving consumers to bear the risk.
4. Profit-Maximization Over Truth: The Lure of a Multi-Million Dollar Misrepresentation
The allegations against Pure Instinct underscore a pervasive issue in modern capitalism: the prioritization of profit maximization, even at the expense of truth and consumer trust.
The lawsuit asserts that the “false and misleading labeling and marketing drives the demand for Products.” The core reason people buy these items is the belief that the pheromones they supposedly contain will attract or influence others.
By allegedly fabricating a scientific basis for their products, Pure Instinct could create a unique selling proposition, justifying a premium price and carving out a niche in the competitive fragrance market.
The complaint argues that if consumers knew the truth—that the products do not contain detectable human pheromones or that humans cannot detect them—the price of these products would “crater.”
This incentive structure, which rewards marketable claims over factual accuracy, is a hallmark of an economic system where shareholder value and revenue growth often overshadow ethical considerations and genuine product efficacy.
The deception is not portrayed as an accidental oversight but as a calculated marketing strategy designed to exploit consumer desires and scientific misunderstandings for financial gain.
5. The Economic Fallout: Consumers Left Empty-Handed
The primary economic consequence detailed in the lawsuit is the financial injury suffered by consumers. Plaintiff India Winslow and the proposed class members allegedly paid for products based on claims of pheromone-induced attraction that the lawsuit deems false.
This harm is framed in two ways: either consumers paid a “price premium” attributable to these misleading statements, or the products are “wholly worthless” because their main advertised benefit is non-existent.
The complaint estimates that the amount in controversy exceeds $5,000,000, indicating a significant number of consumers may have been affected.
This financial loss, multiplied across tens or hundreds of thousands of class members, represents a substantial transfer of wealth from individuals to the corporation, based on what the lawsuit calls “false and misleading marketing practices.” This scenario is common where information asymmetry exists; corporations possess deep knowledge about their products (including alleged flaws), while consumers rely on advertising, which, if deceptive, leads directly to economic detriment.
6. Public Health Under a False Pretense: Misbranded Aphrodisiacs and Consumer Trust
While the Pure Instinct products are not alleged to cause direct physical harm in the way some unsafe products might, the lawsuit raises a public health concern related to their classification and marketing. By allegedly making claims about their ability to “arouse or increase sexual desire” or influence attraction, these products function as unapproved and misbranded aphrodisiac drugs under FDA regulations.
The FDA’s stance (21 C.F.R. § 310.528) underscores that there is no generally recognized safe and effective OTC aphrodisiac. Marketing such products without FDA approval sidesteps the rigorous testing required to establish both safety and efficacy for drugs.
This practice not only potentially violates federal and state law (California’s Sherman Food Drug and Cosmetic Law) but also erodes public trust.
Consumers are led to believe they are purchasing a product with scientifically validated benefits when, as the FDA itself suggests for such claims, they are “false, misleading, or unsupported by scientific data.” This undermining of regulatory standards designed to protect public health and ensure product integrity is a significant concern.
7. The PR Machine: Weaving a Narrative of Scientific Legitimacy
The lawsuit extensively documents Pure Instinct’s alleged “PR machine” – its comprehensive marketing efforts designed to convince consumers of the scientific validity of their pheromone products. This wasn’t a subtle hint; it was a direct and pervasive message. Each product was “prominently labeled with the word ‘Pheromone’.”
The company’s website and product descriptions explicitly claimed the products contained “human-compatible pheromones capable of influencing moods, emotions, and affection and triggering social responses.”
To bolster this, their website featured an image with the text, “It’s not myth, it’s science.
Pheromone imported from Italy.” Specific chemicals, Copulin and Androstadienone, were named as pheromones from females and males used in their formula.
Even the mechanism of action was described, asserting that pheromones are detected through the vomeronasal organ (VNO). Amazon sales pages echoed these claims, describing “The Original Pheromone Infused Essential Oil Perfume Cologne” as an “alluring fragrance[] with human-compatible pheromones.”
These carefully crafted messages, repeated across multiple platforms, created a powerful narrative of scientific backing that was entirely false.
8. Corporate Greed in a Bottle: Exploiting Desires for Profit
The case against Pure Instinct can be seen as a clear example of alleged corporate greed, where the natural human desire for connection and attraction is purportedly exploited for financial gain.
The lawsuit argues that the sole reason reasonable consumers purchase these products is the belief in their pheromone-based efficacy. By manufacturing and marketing products with claims of containing “human-compatible pheromones” that can influence others, despite scientific evidence to the contrary cited in the complaint, the defendants are accused of prioritizing profits over ethical conduct and consumer well-being.
The assertion that “if consumers knew the truth, the price of Defendants’ Products would crater” strongly implies that the value of the products is artificially inflated by these alleged misrepresentations.
This practice of leveraging pseudoscience to create a market for otherwise ordinary items (in this case, fragrances) reflects a business model where the allure of substantial profits derived from misleading claims outweighs the potential risks of regulatory action or litigation. It speaks to a broader culture where corporate ethics can be compromised when significant financial incentives are at play.
9. The Pervasive Nature of Misleading Marketing in Neoliberal Economies
While the Pure Instinct case focuses on specific products, it mirrors a broader pattern of misleading marketing prevalent in neoliberal economies, particularly within the cosmetics, wellness, and supplement industries.
Under such economic systems, which often emphasize deregulation and free-market principles, companies can face intense pressure to differentiate their products and capture market share. This pressure sometimes leads to exaggerated or scientifically unsupported claims designed to appeal to consumer desires for quick fixes, enhanced attractiveness, or improved well-being.
The strategy of invoking “science” without robust, verifiable evidence, as Pure Instinct is accused of doing, is a common tactic. It exploits the public’s general trust in scientific authority while often relying on cherry-picked data, misinterpreted studies, or outright pseudoscience.
Regulatory bodies, often underfunded or with limited mandates for pre-market approval of cosmetic claims, may struggle to keep pace, leaving consumers vulnerable. This environment allows companies to profit from misinformation, externalizing the cost of deception onto the public, until challenged by consumer advocacy groups or legal actions like the one filed against Pure Instinct.
10. Corporate Accountability in Late-Stage Capitalism: A System Under Strain
The lawsuit against Pure Instinct, if its allegations are proven, raises critical questions about corporate accountability within the framework of late-stage capitalism.
The legal complaint argues that the defendants engaged in “unlawful, fraudulent, and unfair conduct” by knowingly making false claims. In an economic system that often appears to prioritize shareholder profits above all else, the mechanisms for holding corporations accountable for such alleged deceptions can seem inadequate or slow.
Even when lawsuits are successful, the penalties—fines, settlements without admission of wrongdoing—may be viewed by some corporations as merely a “cost of doing business” rather than a significant deterrent.
The legal pursuit of redress, as undertaken by India Winslow and the proposed class, is an essential tool for consumer protection. However, its reliance on individual or group action to police corporate behavior highlights potential weaknesses in upfront regulatory enforcement.
The effectiveness of such accountability measures is crucial in determining whether corporations will be incentivized to act ethically or continue to push the boundaries of misleading advertising.
11. Pathways for Reform: Strengthening Consumer Protection in an Era of Pseudoscience
The allegations against Pure Instinct underscore the need for stronger consumer protection mechanisms, particularly in industries prone to pseudoscientific marketing.
One potential pathway for reform involves more stringent regulatory oversight by bodies like the FDA. This could include clearer definitions for products claiming to have physiological effects (like influencing attraction) and requiring a higher burden of proof for such claims before products reach the market, especially if they verge on being drug claims rather than simple cosmetic effects.
Increased funding and authority for regulatory agencies to proactively investigate and penalize misleading advertising could also serve as a deterrent.
Furthermore, promoting scientific literacy among consumers can empower them to critically evaluate product claims. Finally, facilitating collective action, such as class-action lawsuits, remains a vital avenue for consumers to seek redress and hold corporations accountable when regulatory systems fall short. These reforms aim to shift the balance, making it less profitable for companies to engage in deceptive practices and more beneficial to adhere to truth in advertising.
12. This Is the System Working as Intended: Profit Over People
The Pure Instinct case, as detailed in the legal complaint, can be interpreted not merely as an isolated incident of alleged corporate misbehavior, but as an illustration of a system functioning as designed under certain interpretations of neoliberal capitalism.
When profit maximization is the primary driver, and regulatory oversight is limited or reactive, outcomes where consumer well-being or truthfulness are secondary are predictable. The lawsuit alleges that Pure Instinct made a calculated decision to market products based on scientifically dubious claims because it was profitable to do so.
The ability to generate significant revenue (implied by the $5 million+ in controversy) from products whose core advertised benefit is allegedly non-existent suggests that the system allows, and perhaps even incentivizes, such behavior until challenged. The “fix” often comes not from proactive regulation preventing the harm, but from costly and time-consuming litigation after consumers have already suffered financial loss.
This reactive approach, where harm is monetized first and potentially rectified later, can be seen as a feature, not a bug, of an economic model that prioritizes corporate freedom and market mechanisms over preemptive consumer protection.
13. Conclusion: Beyond Fragrance, A Question of Corporate Integrity
The class-action lawsuit against W.T.F.N. Inc. and Oui Lab, Inc. transcends a simple dispute over the efficacy of scented oils and sprays. It probes deeply into the responsibilities corporations have to their customers and the ethical lines that should not be crossed in the pursuit of profit.
The allegations that Pure Instinct knowingly marketed products based on “scientifically false” claims about pheromones—exploiting consumers’ desires and misunderstanding of science—are serious and speak to a potential breach of trust.
This case serves as a critical reminder of the power dynamics in the marketplace. Corporations, with their significant marketing budgets and access to information, can shape consumer perceptions.
When this power is allegedly abused through deceptive practices, the financial injury to individuals can be substantial, and the erosion of overall consumer confidence in advertising can be profound. The outcome of this legal battle will be watched closely, not just for its impact on the defendants, but for the broader message it sends about corporate accountability and the value of truth in the modern marketplace.
14. Frivolous or Serious Lawsuit? Assessing the Claims Against Pure Instinct
Based on the detailed allegations and the scientific counter-evidence presented in the complaint (Case 2:25-cv-01393), the lawsuit against Pure Instinct appears to represent a serious legal grievance rather than a frivolous claim.
The legal complaint is not based on subjective dissatisfaction with a fragrance’s scent, but on specific, verifiable claims made by the company about the products’ composition and scientifically proven effects—claims that the lawsuit systematically attempts to dismantle using scientific literature and FDA regulatory context.
The core of the suit rests on the assertion that Pure Instinct’s marketing is built on falsehoods regarding human biology (the functionality of the VNO) and the nature of the chemicals used (androstadienone and copulin as human pheromones).
The citation of FDA regulations concerning aphrodisiac drug products further grounds the complaint in established legal and regulatory frameworks.
Given the detailed factual allegations, the specific examples of misleading advertising, and the clear articulation of financial harm to consumers, this lawsuit reflects a significant challenge to what it portrays as systemic corporate deception, warranting thorough judicial review.
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
